This article is maintained by: Elsevier
Article Title: Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials
Journal Title: The Lancet Diabetes & Endocrinology
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/S2213-8587(20)30364-8
CrossRef DOI link to the associated document: https://doi.org/10.1016/S2213-8587(20)30366-1
Content Type: article
Copyright: © 2020 Elsevier Ltd. All rights reserved.